These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
681 related articles for article (PubMed ID: 26286337)
1. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. Gathe J; Arribas JR; Van Lunzen J; Garner W; Speck RM; Bender R; Shreay S; Nguyen T Patient; 2015 Oct; 8(5):445-54. PubMed ID: 26286337 [TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF. Mills A; Garner W; Pozniak A; Berenguer J; Speck RM; Bender R; Nguyen T Patient; 2015 Aug; 8(4):359-71. PubMed ID: 26045359 [TBL] [Abstract][Full Text] [Related]
3. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551 [TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial. Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940 [TBL] [Abstract][Full Text] [Related]
5. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP; Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590 [TBL] [Abstract][Full Text] [Related]
6. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. Arribas JR; DeJesus E; van Lunzen J; Zurawski C; Doroana M; Towner W; Lazzarin A; Nelson M; McColl D; Andreatta K; Swamy R; Szwarcberg J; Nguyen T HIV Clin Trials; 2017 May; 18(3):118-125. PubMed ID: 28555519 [TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J; J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366 [TBL] [Abstract][Full Text] [Related]
8. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study. Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects. Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802 [TBL] [Abstract][Full Text] [Related]
10. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. Pozniak A; Flamm J; Antinori A; Bloch M; Ward D; Berenguer J; Cote P; Andreatta K; Garner W; Szwarcberg J; Nguyen-Cleary T; McColl DJ; Piontkowsky D HIV Clin Trials; 2017 Jul; 18(4):141-148. PubMed ID: 28689453 [TBL] [Abstract][Full Text] [Related]
11. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients. Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960 [TBL] [Abstract][Full Text] [Related]
12. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057 [TBL] [Abstract][Full Text] [Related]
13. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients. Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601 [TBL] [Abstract][Full Text] [Related]
14. Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128). Kulkarni R; Hodder SL; Cao H; Chang S; Miller MD; White KL HIV Clin Trials; 2017 Jul; 18(4):164-173. PubMed ID: 28891788 [TBL] [Abstract][Full Text] [Related]
15. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Pozniak A; Markowitz M; Mills A; Stellbrink HJ; Antela A; Domingo P; Girard PM; Henry K; Nguyen T; Piontkowsky D; Garner W; White K; Guyer B Lancet Infect Dis; 2014 Jul; 14(7):590-9. PubMed ID: 24908550 [TBL] [Abstract][Full Text] [Related]
16. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. Angione SA; Cherian SM; Özdener AE J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493 [TBL] [Abstract][Full Text] [Related]
17. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK; Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591 [TBL] [Abstract][Full Text] [Related]
18. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. White KL; Kulkarni R; McColl DJ; Rhee MS; Szwarcberg J; Cheng AK; Miller MD Antivir Ther; 2015; 20(3):317-27. PubMed ID: 25321623 [TBL] [Abstract][Full Text] [Related]
19. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486 [TBL] [Abstract][Full Text] [Related]